Entity > Corporation > US > New York City New York > Pear Therapeutics

About Pear Therapeutics

Pear Therapeutics Inc. is a biotechnology and software company providing digital therapeutic platforms to treat disease and improve drug efficacy. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants.

Pear Therapeutics, Inc. Offers Prescription Digital Therapeutics (PDTs): Prescription digital therapeutics from Pear Therapeutics are software-based treatments for diseases in therapeutic areas such as psychiatric and neurological disorders. Pear Therapeutics was the first company in the world to receive Food and Drug Administration (FDA) approval for PDTs, which are claimed to improve clinical outcomes of diseases.

Pear Therapeutics, Inc. Has The First Three PDTs Approved By the FDA To Treat Diseases: Pear Therapeutics' first product, reSET, for the treatment of substance use disorders, was the first PDT to receive FDA approval for the treatment of disease. The second product, reSET-O, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. The third product, Somryst, for the treatment of chronic insomnia, was the first PDT submitted through the FDA's traditional 510(k) pathway and simultaneously reviewed under the FDA's Software Precertification Pilot Program.

Founding: Pear Therapeutics, Inc. is headquartered in Boston, Massachusetts, and was founded in 2013 by Corey McCann, Stephen Smith, and William Greene.

Industry: Business & Industrial > Pharmaceuticals & Biotech

More information about Pear Therapeutics